Trials / Completed
CompletedNCT01512420
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
A Multicenter, Prospective, Observational Study to Identify Different Prognostic Factors Related to Survival in Patients With Previously Treated Advanced NSCLC With Wild-type Epidermal Growth Factor Receptor (EGFR) Gene.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 355 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of second-line Tarceva (erlotinib) in patients with previously treated advanced non-small cell lung cancer with confirmed wild-type epidermal growth factor receptor (EGFR) gene. The aim of the study is to identify from baseline clinical and demographic patient characteristics prognostic factors related to overall survival with second-line Tarceva treatment. Data will be collected from eligible patients for up to 2 years.
Conditions
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2012-01-19
- Last updated
- 2016-11-02
Locations
41 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01512420. Inclusion in this directory is not an endorsement.